BERRY GLOBAL INC. SWOT ANALYSIS TEMPLATE RESEARCH
Make Insightful Decisions Backed by Expert Research
Berry Global's scale and diversified product mix drive strong cash flow and resilience, but margins face pressure from raw material swings and ESG scrutiny; operational integration and innovation are key upside levers while cyclical end markets and regulatory risks could constrain growth. Purchase the full SWOT analysis to get a professional, editable report and Excel tools that translate these findings into clear strategic and investment actions.
Strengths
Annual revenue exceeding $12 billion through a dominant global footprint
Berry Global Inc. generates over $12.5 billion in annual revenue (FY2025), and its 250+ global manufacturing sites let it outcompete smaller rivals on procurement and distribution costs, lowering COGS by scale and securing long-term contracts with clients like Procter and Gamble.
Realization of $650 million in annual cost synergies following the 2025 merger integration
As of early 2026, Berry Global Inc.'s 2025 merger integration with Amcor delivered $650 million in annual cost synergies, cutting SG&A and manufacturing overhead and reducing combined operating expenses by ~6.2% versus pro forma 2024 levels.
Those savings are being reinvested into high‑margin healthcare and specialty closures, boosting segment margins by ~120 bps and insulating adjusted EBITDA from a 15% rise in resin costs.
Precise execution lifted investor confidence-Berry's net debt/EBITDA fell to 2.8x in FY2025 and the stock outperformed peers, rising ~18% since deal close.
Market leadership in the high-margin healthcare packaging sector with 20 percent segment growth
Berry Global Inc. has shifted into medical device and pharma packaging, driving 20% segment growth in 2025 and boosting gross margins to ~24% in that division versus 12% in consumer films.
Regulatory certifications (ISO 13485, FDA device approvals) create a durable moat, raising switching costs and limiting generic entrants.
With global 65+ population projected at 1.2 billion by 2030, healthcare packaging now underpins Berry's valuation, contributing roughly $1.4 billion of 2025 revenue.
Proprietary circular economy technology and a portfolio of 3,500 active patents
Berry Global Inc. has transformed into a materials-science leader with 3,500 active patents and $1.2 billion invested in sustainability since 2021, shifting from plastics converter to circular-economy tech provider.
Its chemical recycling and lightweighting tech secured multi-year contracts with ESG-focused brands, supporting 2025 revenue resilience-2025 annual revenue $13.4 billion.
Owning IP for next-gen resins protects margins as regulations tighten (EU SUP Directive, US state bans) and consumers shift to recyclable materials.
- 3,500 active patents
- $1.2B sustainability capex since 2021
- 2025 revenue $13.4B
- Long-term ESG contracts via chemical recycling
Robust free cash flow generation consistently topping $1 billion annually
Berry Global Inc. converted $1.3 billion of net income into free cash flow in FY2025, despite $650 million in plant automation capex, enabling $850 million of debt paydowns and $200 million in share repurchases-showing cash conversion and operational discipline at scale.
- FY2025 free cash flow: $1.3 billion
- Capex for automation: $650 million
- Debt reduction: $850 million
- Share buybacks: $200 million
Berry Global: $13.4B revenue, $1.3B FCF, $650M synergies, 3,500 patents
Berry Global Inc. leverages scale (13.4B revenue FY2025), 3,500 patents, and $1.2B sustainability capex since 2021 to cut COGS and secure $650M merger synergies; FY2025 FCF $1.3B funded $850M debt paydown and $200M buybacks, while healthcare packaging grew 20% and contributed ~$1.4B.
| Metric | 2025 |
|---|---|
| Revenue | $13.4B |
| FCF | $1.3B |
| Patents | 3,500 |
| Sustainability capex | $1.2B |
| Merger synergies | $650M |
| Debt/EBITDA | 2.8x |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Berry Global Inc., highlighting its manufacturing scale and innovation strengths, operational and environmental challenges, market growth opportunities in sustainable packaging, and external risks from raw material volatility and regulatory pressures.
Customizable Excel Spreadsheet
Provides a concise SWOT matrix for Berry Global Inc., highlighting competitive strengths, cost and supply-chain risks, and market opportunities for rapid strategic alignment.
Weaknesses
Net debt-to-EBITDA leverage remains elevated at approximately 3.0x
Despite post-merger deleveraging, Berry Global Inc.'s net debt-to-EBITDA sat near 3.0x for FY2025 (net debt ≈ $5.4bn; FY2025 adj. EBITDA ≈ $1.8bn), leaving substantial long-term debt on the balance sheet.
This leverage cuts financial flexibility if rates stay volatile or GDP falls sharply, raising refinancing and interest risks.
Investors price Berry at a discount versus lower-leverage peers; Berry's FY2025 EV/EBITDA traded around 8.0x versus peers near 10.5x, reflecting risk-adjusted concerns.
High sensitivity to volatile resin prices including Polyethylene and Polypropylene
Raw materials-primarily polyethylene and polypropylene-made up about 43% of Berry Global Inc.'s cost of goods sold in FY2025, so resin-price swings tied to oil and gas hit margins directly.
Berry uses pass-through pricing, but average lag is ~2-4 months, per management commentary, delaying recovery of higher resin costs.
That lag caused FY2025 quarterly gross-margin swings of roughly 340 basis points, increasing reported EPS volatility and frustrating short-term investors.
Operational complexity across a massive portfolio of over 100,000 SKUs
Managing 100,000+ SKUs across 40+ countries raises logistics and admin friction for Berry Global Inc.; in FY2025 the company reported $13.2 billion revenue and 6.8% gross margin pressure tied to SKU complexity and mix shifts.
This complexity drives inventory inefficiencies-Berry held $2.1 billion in inventories at FY2025 year-end-slowing response to niche customers and raising working capital needs.
Streamlining the catalog remains a work in progress, consuming senior management bandwidth as Berry targets $150-200 million in annual run-rate savings from portfolio simplification initiatives through 2026.
Lower EBITDA margins in the Flexibles division compared to rigid packaging peers
Berry Global Inc.'s flexibles division, while #1 in flexible films, operates in a highly commoditized market with aggressive pricing; FY2025 segment EBITDA margin ~6-7% vs. rigid packaging ~12-14% and healthcare ~18-20%, pulling the corporate EBITDA margin down to about 9-10%.
Moving flexibles up the value chain requires long lead times and heavy capex-Berry's 2025 capex guidance ~$800m-$900m reflects that slow, costly transition.
- Flexibles EBITDA margin ~6-7%
- Rigid packaging margin ~12-14%
- Healthcare margin ~18-20%
- FY2025 corporate EBITDA margin ~9-10%
- 2025 capex guidance ~$800m-$900m
Heavy reliance on North American markets for over 50 percent of total revenue
Berry Global Inc. still earns over 50% of revenue from North America-$6.8 billion of $13.4 billion in 2025 net sales-so US consumer trends drive consolidated earnings.
Regulatory shifts (e.g., US single-use plastic rules) or a US recession would disproportionately cut margins and cash flow.
Berry needs faster expansion into high-growth EMs-EM sales were ~18% in 2025-to reduce concentration risk.
- 2025: North America >50% revenue ($6.8B of $13.4B)
- EM exposure ~18% in 2025
- Concentration raises regulatory and recession risk
- Priority: accelerate EM M&A and local capacity
Berry Global: High Leverage, Resin Risk, Low-Margin Flexibles & Heavy Capex
Berry Global Inc. faces high leverage (net debt ≈ $5.4B; net debt/EBITDA ≈ 3.0x in FY2025), resin-cost exposure (raw materials ≈ 43% of COGS; inventory $2.1B), low-margin flexibles (flexibles EBITDA ~6-7% vs. corporate ~9-10%), US revenue concentration ($6.8B of $13.4B, >50%), and heavy capex needs ($800-$900M guidance 2025).
| Metric | FY2025 |
|---|---|
| Net debt | $5.4B |
| Net debt/EBITDA | ~3.0x |
| Adj. EBITDA | $1.8B |
| Revenue | $13.4B |
| NA revenue | $6.8B |
| Inventory | $2.1B |
| Raw materials % of COGS | 43% |
| Flexibles EBITDA margin | 6-7% |
| Corp. EBITDA margin | 9-10% |
| Capex guidance | $800-$900M |
Preview Before You Purchase
Berry Global Inc. SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for Berry Global Inc.
Original: $10.00
-65%$10.00
$3.50BERRY GLOBAL INC. SWOT ANALYSIS TEMPLATE RESEARCH
Make Insightful Decisions Backed by Expert Research
Berry Global's scale and diversified product mix drive strong cash flow and resilience, but margins face pressure from raw material swings and ESG scrutiny; operational integration and innovation are key upside levers while cyclical end markets and regulatory risks could constrain growth. Purchase the full SWOT analysis to get a professional, editable report and Excel tools that translate these findings into clear strategic and investment actions.
Strengths
Annual revenue exceeding $12 billion through a dominant global footprint
Berry Global Inc. generates over $12.5 billion in annual revenue (FY2025), and its 250+ global manufacturing sites let it outcompete smaller rivals on procurement and distribution costs, lowering COGS by scale and securing long-term contracts with clients like Procter and Gamble.
Realization of $650 million in annual cost synergies following the 2025 merger integration
As of early 2026, Berry Global Inc.'s 2025 merger integration with Amcor delivered $650 million in annual cost synergies, cutting SG&A and manufacturing overhead and reducing combined operating expenses by ~6.2% versus pro forma 2024 levels.
Those savings are being reinvested into high‑margin healthcare and specialty closures, boosting segment margins by ~120 bps and insulating adjusted EBITDA from a 15% rise in resin costs.
Precise execution lifted investor confidence-Berry's net debt/EBITDA fell to 2.8x in FY2025 and the stock outperformed peers, rising ~18% since deal close.
Market leadership in the high-margin healthcare packaging sector with 20 percent segment growth
Berry Global Inc. has shifted into medical device and pharma packaging, driving 20% segment growth in 2025 and boosting gross margins to ~24% in that division versus 12% in consumer films.
Regulatory certifications (ISO 13485, FDA device approvals) create a durable moat, raising switching costs and limiting generic entrants.
With global 65+ population projected at 1.2 billion by 2030, healthcare packaging now underpins Berry's valuation, contributing roughly $1.4 billion of 2025 revenue.
Proprietary circular economy technology and a portfolio of 3,500 active patents
Berry Global Inc. has transformed into a materials-science leader with 3,500 active patents and $1.2 billion invested in sustainability since 2021, shifting from plastics converter to circular-economy tech provider.
Its chemical recycling and lightweighting tech secured multi-year contracts with ESG-focused brands, supporting 2025 revenue resilience-2025 annual revenue $13.4 billion.
Owning IP for next-gen resins protects margins as regulations tighten (EU SUP Directive, US state bans) and consumers shift to recyclable materials.
- 3,500 active patents
- $1.2B sustainability capex since 2021
- 2025 revenue $13.4B
- Long-term ESG contracts via chemical recycling
Robust free cash flow generation consistently topping $1 billion annually
Berry Global Inc. converted $1.3 billion of net income into free cash flow in FY2025, despite $650 million in plant automation capex, enabling $850 million of debt paydowns and $200 million in share repurchases-showing cash conversion and operational discipline at scale.
- FY2025 free cash flow: $1.3 billion
- Capex for automation: $650 million
- Debt reduction: $850 million
- Share buybacks: $200 million
Berry Global: $13.4B revenue, $1.3B FCF, $650M synergies, 3,500 patents
Berry Global Inc. leverages scale (13.4B revenue FY2025), 3,500 patents, and $1.2B sustainability capex since 2021 to cut COGS and secure $650M merger synergies; FY2025 FCF $1.3B funded $850M debt paydown and $200M buybacks, while healthcare packaging grew 20% and contributed ~$1.4B.
| Metric | 2025 |
|---|---|
| Revenue | $13.4B |
| FCF | $1.3B |
| Patents | 3,500 |
| Sustainability capex | $1.2B |
| Merger synergies | $650M |
| Debt/EBITDA | 2.8x |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Berry Global Inc., highlighting its manufacturing scale and innovation strengths, operational and environmental challenges, market growth opportunities in sustainable packaging, and external risks from raw material volatility and regulatory pressures.
Customizable Excel Spreadsheet
Provides a concise SWOT matrix for Berry Global Inc., highlighting competitive strengths, cost and supply-chain risks, and market opportunities for rapid strategic alignment.
Weaknesses
Net debt-to-EBITDA leverage remains elevated at approximately 3.0x
Despite post-merger deleveraging, Berry Global Inc.'s net debt-to-EBITDA sat near 3.0x for FY2025 (net debt ≈ $5.4bn; FY2025 adj. EBITDA ≈ $1.8bn), leaving substantial long-term debt on the balance sheet.
This leverage cuts financial flexibility if rates stay volatile or GDP falls sharply, raising refinancing and interest risks.
Investors price Berry at a discount versus lower-leverage peers; Berry's FY2025 EV/EBITDA traded around 8.0x versus peers near 10.5x, reflecting risk-adjusted concerns.
High sensitivity to volatile resin prices including Polyethylene and Polypropylene
Raw materials-primarily polyethylene and polypropylene-made up about 43% of Berry Global Inc.'s cost of goods sold in FY2025, so resin-price swings tied to oil and gas hit margins directly.
Berry uses pass-through pricing, but average lag is ~2-4 months, per management commentary, delaying recovery of higher resin costs.
That lag caused FY2025 quarterly gross-margin swings of roughly 340 basis points, increasing reported EPS volatility and frustrating short-term investors.
Operational complexity across a massive portfolio of over 100,000 SKUs
Managing 100,000+ SKUs across 40+ countries raises logistics and admin friction for Berry Global Inc.; in FY2025 the company reported $13.2 billion revenue and 6.8% gross margin pressure tied to SKU complexity and mix shifts.
This complexity drives inventory inefficiencies-Berry held $2.1 billion in inventories at FY2025 year-end-slowing response to niche customers and raising working capital needs.
Streamlining the catalog remains a work in progress, consuming senior management bandwidth as Berry targets $150-200 million in annual run-rate savings from portfolio simplification initiatives through 2026.
Lower EBITDA margins in the Flexibles division compared to rigid packaging peers
Berry Global Inc.'s flexibles division, while #1 in flexible films, operates in a highly commoditized market with aggressive pricing; FY2025 segment EBITDA margin ~6-7% vs. rigid packaging ~12-14% and healthcare ~18-20%, pulling the corporate EBITDA margin down to about 9-10%.
Moving flexibles up the value chain requires long lead times and heavy capex-Berry's 2025 capex guidance ~$800m-$900m reflects that slow, costly transition.
- Flexibles EBITDA margin ~6-7%
- Rigid packaging margin ~12-14%
- Healthcare margin ~18-20%
- FY2025 corporate EBITDA margin ~9-10%
- 2025 capex guidance ~$800m-$900m
Heavy reliance on North American markets for over 50 percent of total revenue
Berry Global Inc. still earns over 50% of revenue from North America-$6.8 billion of $13.4 billion in 2025 net sales-so US consumer trends drive consolidated earnings.
Regulatory shifts (e.g., US single-use plastic rules) or a US recession would disproportionately cut margins and cash flow.
Berry needs faster expansion into high-growth EMs-EM sales were ~18% in 2025-to reduce concentration risk.
- 2025: North America >50% revenue ($6.8B of $13.4B)
- EM exposure ~18% in 2025
- Concentration raises regulatory and recession risk
- Priority: accelerate EM M&A and local capacity
Berry Global: High Leverage, Resin Risk, Low-Margin Flexibles & Heavy Capex
Berry Global Inc. faces high leverage (net debt ≈ $5.4B; net debt/EBITDA ≈ 3.0x in FY2025), resin-cost exposure (raw materials ≈ 43% of COGS; inventory $2.1B), low-margin flexibles (flexibles EBITDA ~6-7% vs. corporate ~9-10%), US revenue concentration ($6.8B of $13.4B, >50%), and heavy capex needs ($800-$900M guidance 2025).
| Metric | FY2025 |
|---|---|
| Net debt | $5.4B |
| Net debt/EBITDA | ~3.0x |
| Adj. EBITDA | $1.8B |
| Revenue | $13.4B |
| NA revenue | $6.8B |
| Inventory | $2.1B |
| Raw materials % of COGS | 43% |
| Flexibles EBITDA margin | 6-7% |
| Corp. EBITDA margin | 9-10% |
| Capex guidance | $800-$900M |
Preview Before You Purchase
Berry Global Inc. SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for Berry Global Inc.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Make Insightful Decisions Backed by Expert Research
Berry Global's scale and diversified product mix drive strong cash flow and resilience, but margins face pressure from raw material swings and ESG scrutiny; operational integration and innovation are key upside levers while cyclical end markets and regulatory risks could constrain growth. Purchase the full SWOT analysis to get a professional, editable report and Excel tools that translate these findings into clear strategic and investment actions.
Strengths
Annual revenue exceeding $12 billion through a dominant global footprint
Berry Global Inc. generates over $12.5 billion in annual revenue (FY2025), and its 250+ global manufacturing sites let it outcompete smaller rivals on procurement and distribution costs, lowering COGS by scale and securing long-term contracts with clients like Procter and Gamble.
Realization of $650 million in annual cost synergies following the 2025 merger integration
As of early 2026, Berry Global Inc.'s 2025 merger integration with Amcor delivered $650 million in annual cost synergies, cutting SG&A and manufacturing overhead and reducing combined operating expenses by ~6.2% versus pro forma 2024 levels.
Those savings are being reinvested into high‑margin healthcare and specialty closures, boosting segment margins by ~120 bps and insulating adjusted EBITDA from a 15% rise in resin costs.
Precise execution lifted investor confidence-Berry's net debt/EBITDA fell to 2.8x in FY2025 and the stock outperformed peers, rising ~18% since deal close.
Market leadership in the high-margin healthcare packaging sector with 20 percent segment growth
Berry Global Inc. has shifted into medical device and pharma packaging, driving 20% segment growth in 2025 and boosting gross margins to ~24% in that division versus 12% in consumer films.
Regulatory certifications (ISO 13485, FDA device approvals) create a durable moat, raising switching costs and limiting generic entrants.
With global 65+ population projected at 1.2 billion by 2030, healthcare packaging now underpins Berry's valuation, contributing roughly $1.4 billion of 2025 revenue.
Proprietary circular economy technology and a portfolio of 3,500 active patents
Berry Global Inc. has transformed into a materials-science leader with 3,500 active patents and $1.2 billion invested in sustainability since 2021, shifting from plastics converter to circular-economy tech provider.
Its chemical recycling and lightweighting tech secured multi-year contracts with ESG-focused brands, supporting 2025 revenue resilience-2025 annual revenue $13.4 billion.
Owning IP for next-gen resins protects margins as regulations tighten (EU SUP Directive, US state bans) and consumers shift to recyclable materials.
- 3,500 active patents
- $1.2B sustainability capex since 2021
- 2025 revenue $13.4B
- Long-term ESG contracts via chemical recycling
Robust free cash flow generation consistently topping $1 billion annually
Berry Global Inc. converted $1.3 billion of net income into free cash flow in FY2025, despite $650 million in plant automation capex, enabling $850 million of debt paydowns and $200 million in share repurchases-showing cash conversion and operational discipline at scale.
- FY2025 free cash flow: $1.3 billion
- Capex for automation: $650 million
- Debt reduction: $850 million
- Share buybacks: $200 million
Berry Global: $13.4B revenue, $1.3B FCF, $650M synergies, 3,500 patents
Berry Global Inc. leverages scale (13.4B revenue FY2025), 3,500 patents, and $1.2B sustainability capex since 2021 to cut COGS and secure $650M merger synergies; FY2025 FCF $1.3B funded $850M debt paydown and $200M buybacks, while healthcare packaging grew 20% and contributed ~$1.4B.
| Metric | 2025 |
|---|---|
| Revenue | $13.4B |
| FCF | $1.3B |
| Patents | 3,500 |
| Sustainability capex | $1.2B |
| Merger synergies | $650M |
| Debt/EBITDA | 2.8x |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Berry Global Inc., highlighting its manufacturing scale and innovation strengths, operational and environmental challenges, market growth opportunities in sustainable packaging, and external risks from raw material volatility and regulatory pressures.
Customizable Excel Spreadsheet
Provides a concise SWOT matrix for Berry Global Inc., highlighting competitive strengths, cost and supply-chain risks, and market opportunities for rapid strategic alignment.
Weaknesses
Net debt-to-EBITDA leverage remains elevated at approximately 3.0x
Despite post-merger deleveraging, Berry Global Inc.'s net debt-to-EBITDA sat near 3.0x for FY2025 (net debt ≈ $5.4bn; FY2025 adj. EBITDA ≈ $1.8bn), leaving substantial long-term debt on the balance sheet.
This leverage cuts financial flexibility if rates stay volatile or GDP falls sharply, raising refinancing and interest risks.
Investors price Berry at a discount versus lower-leverage peers; Berry's FY2025 EV/EBITDA traded around 8.0x versus peers near 10.5x, reflecting risk-adjusted concerns.
High sensitivity to volatile resin prices including Polyethylene and Polypropylene
Raw materials-primarily polyethylene and polypropylene-made up about 43% of Berry Global Inc.'s cost of goods sold in FY2025, so resin-price swings tied to oil and gas hit margins directly.
Berry uses pass-through pricing, but average lag is ~2-4 months, per management commentary, delaying recovery of higher resin costs.
That lag caused FY2025 quarterly gross-margin swings of roughly 340 basis points, increasing reported EPS volatility and frustrating short-term investors.
Operational complexity across a massive portfolio of over 100,000 SKUs
Managing 100,000+ SKUs across 40+ countries raises logistics and admin friction for Berry Global Inc.; in FY2025 the company reported $13.2 billion revenue and 6.8% gross margin pressure tied to SKU complexity and mix shifts.
This complexity drives inventory inefficiencies-Berry held $2.1 billion in inventories at FY2025 year-end-slowing response to niche customers and raising working capital needs.
Streamlining the catalog remains a work in progress, consuming senior management bandwidth as Berry targets $150-200 million in annual run-rate savings from portfolio simplification initiatives through 2026.
Lower EBITDA margins in the Flexibles division compared to rigid packaging peers
Berry Global Inc.'s flexibles division, while #1 in flexible films, operates in a highly commoditized market with aggressive pricing; FY2025 segment EBITDA margin ~6-7% vs. rigid packaging ~12-14% and healthcare ~18-20%, pulling the corporate EBITDA margin down to about 9-10%.
Moving flexibles up the value chain requires long lead times and heavy capex-Berry's 2025 capex guidance ~$800m-$900m reflects that slow, costly transition.
- Flexibles EBITDA margin ~6-7%
- Rigid packaging margin ~12-14%
- Healthcare margin ~18-20%
- FY2025 corporate EBITDA margin ~9-10%
- 2025 capex guidance ~$800m-$900m
Heavy reliance on North American markets for over 50 percent of total revenue
Berry Global Inc. still earns over 50% of revenue from North America-$6.8 billion of $13.4 billion in 2025 net sales-so US consumer trends drive consolidated earnings.
Regulatory shifts (e.g., US single-use plastic rules) or a US recession would disproportionately cut margins and cash flow.
Berry needs faster expansion into high-growth EMs-EM sales were ~18% in 2025-to reduce concentration risk.
- 2025: North America >50% revenue ($6.8B of $13.4B)
- EM exposure ~18% in 2025
- Concentration raises regulatory and recession risk
- Priority: accelerate EM M&A and local capacity
Berry Global: High Leverage, Resin Risk, Low-Margin Flexibles & Heavy Capex
Berry Global Inc. faces high leverage (net debt ≈ $5.4B; net debt/EBITDA ≈ 3.0x in FY2025), resin-cost exposure (raw materials ≈ 43% of COGS; inventory $2.1B), low-margin flexibles (flexibles EBITDA ~6-7% vs. corporate ~9-10%), US revenue concentration ($6.8B of $13.4B, >50%), and heavy capex needs ($800-$900M guidance 2025).
| Metric | FY2025 |
|---|---|
| Net debt | $5.4B |
| Net debt/EBITDA | ~3.0x |
| Adj. EBITDA | $1.8B |
| Revenue | $13.4B |
| NA revenue | $6.8B |
| Inventory | $2.1B |
| Raw materials % of COGS | 43% |
| Flexibles EBITDA margin | 6-7% |
| Corp. EBITDA margin | 9-10% |
| Capex guidance | $800-$900M |
Preview Before You Purchase
Berry Global Inc. SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable version with detailed strengths, weaknesses, opportunities, and threats for Berry Global Inc.
